BRIEF published on 12/09/2025 at 14:55, 7 days 5 hours ago Teva Pharmaceuticals submits an application for authorization for Olanzapine LAI FDA Schizophrenia Medincell Teva Pharmaceuticals Olanzapine LAI
BRIEF published on 12/09/2025 at 14:55, 7 days 5 hours ago Medincell and Teva Submit FDA Application for New Injectable Treatment Schizophrenia Treatment Medincell FDA Submission Teva Pharmaceuticals Olanzapine LAI
PRESS RELEASE published on 12/09/2025 at 14:50, 7 days 5 hours ago Inside Information / Other news releases Teva Pharmaceuticals submits NDA to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749 / mdc-TJK) for Once-Monthly Schizophrenia Treatment. Medincell focuses on long-acting injectable treatments across therapeutic areas Schizophrenia Medincell Olanzapine NDA Teva Pharmaceuticals
BRIEF published on 11/11/2025 at 08:05, 1 month 5 days ago Medincell Expands Dr Grace Kim's Role to Boost US Capital Growth Biotechnology Medincell Pharmaceutical Strategy Dr Grace Kim US Capital Growth
PRESS RELEASE published on 11/11/2025 at 08:00, 1 month 5 days ago Inside Information / Other news releases Medincell appoints Dr. Grace Kim as Chief Strategy Officer, U.S. Finance to lead U.S. capital growth strategy. Medincell pioneers long-acting injectable therapies Medincell Dr. Grace Kim Long-acting Injectable Therapies U.S. Capital Growth Clinical-stage Pharmaceutical Company
BRIEF published on 11/05/2025 at 13:51, 1 month 11 days ago Continued growth for Medincell and new prospects with Olanzapine LAI Schizophrenia Medincell Teva Pharmaceuticals Olanzapine LAI UZEDY
PRESS RELEASE published on 11/05/2025 at 13:46, 1 month 11 days ago Inside Information / Other news releases Medincell's partner Teva plans US NDA submission for Olanzapine LAI in Q4 2025, while UZEDY® achieves continued growth in sales in Q3 2025 Medincell Teva Pharmaceuticals Olanzapine LAI US NDA Submission UZEDY Sales Growth
BRIEF published on 10/10/2025 at 22:16, 2 months 5 days ago FDA Approves UZEDY for Bipolar I Disorder in Adults FDA Approval Mental Health Treatment UZEDY Bipolar I Disorder Risperidone
PRESS RELEASE published on 10/10/2025 at 22:11, 2 months 5 days ago Inside Information / Other news releases FDA approves UZEDY as extended-release injectable suspension for bipolar I disorder treatment in adults. Teva and Medincell collaborate on this significant advancement in neuroscience FDA Medincell Teva UZEDY Bipolar I Disorder
BRIEF published on 09/17/2025 at 14:05, 2 months 29 days ago Medincell and Teva Present Phase 3 Olanzapine LAI Data Phase 3 Trial Schizophrenia Treatment Medincell Teva Olanzapine LAI
Published on 12/16/2025 at 19:25, 46 minutes ago Cypher Metaverse Inc. Announces Signing of Definitive Agreement for Acquisition
Published on 12/16/2025 at 18:00, 2 hours 11 minutes ago RTO SPA Terminated: Mumena Mushinge, Brian Chasala, Terra Metals Inc. and Terra Metals Limited Failed to Provide Necessary Due Diligence Information and Failed to File CSE Application
Published on 12/16/2025 at 14:30, 5 hours 41 minutes ago Worksport Launches Rivian R1T Pickup Truck Compatible Cover, SOLIS Solar Tonneau
Published on 12/16/2025 at 14:00, 6 hours 11 minutes ago QNX Embedded Technology Now Powering More Than 275 Million Vehicles on the Road
Published on 12/16/2025 at 14:00, 6 hours 11 minutes ago Loop Industries and Ester Industries' India Joint Venture Awards Detailed Engineering Contract to Toyo for Infinite Loop(TM) India
Published on 12/16/2025 at 18:30, 1 hour 41 minutes ago SIX Exchange Regulation approves delisting of u-blox registered shares and grants exemption from specific disclosure requirements
Published on 12/16/2025 at 17:32, 2 hours 39 minutes ago M&G Credit Income Investment Trust plc: Net Asset Value(s)
Published on 12/16/2025 at 18:53, 1 hour 18 minutes ago Number of shares and voting rights - November 2025 (In French only)
Published on 12/16/2025 at 18:10, 2 hours 1 minute ago Amundi crosses the statutory threshold of 2% upwards
Published on 12/16/2025 at 17:45, 2 hours 26 minutes ago Imerys-December-2025-information-share-capital-and-voting-rights-as-of-30-November-2025
Published on 12/16/2025 at 17:43, 2 hours 28 minutes ago Aéroports de Paris S.A - November 2025 traffic figures
Published on 12/16/2025 at 08:30, 11 hours 41 minutes ago Cie du Bois Sauvage: Buy back of own shares – week from 08/12/2025 to 12/12/2025
